Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
COO — frequently asked questions
Is The Cooper Companies, Inc. overvalued?
In our latest published analysis dated 2026-09-20, COO looks meaningfully undervalued. The price recorded at analysis is 55,3 USD versus our fair value of 78,5 USD; the high endpoint is presented separately as potential value of 92,7 USD. That implies roughly 41.9% upside to fair value at that date.
Our latest published report, analyzed 2026-09-20, gives COO a fair value of 78,5 USD and a potential value of 92,7 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for The Cooper Companies, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy COO now?
Our latest published rating for COO, analyzed 2026-09-20, is Strong Buy. The Cooper Companies, Inc. looks meaningfully undervalued at the analysis-date price of 55,3 USD versus fair value of 78,5 USD; potential value is 92,7 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for COO?
The dedicated bear-case section in our report analyzed 2026-09-20 documents The Cooper Companies, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is COO's rating?
Our latest published rating for COO, analyzed 2026-09-20, is Strong Buy, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of 78,5 USD, the potential value of 92,7 USD, and the price recorded at analysis (55,3 USD).
Affichage de la source anglaise pendant la traduction
Ce rapport n'a pas encore été traduit. Actualisez dans quelques minutes une fois que la file d'attente de traduction aura rattrapé son retard.
§1 RésuméEN
Réponse en 30 secondesStrong Buy
Prix par rapport à la valeur
Cours
$55.29
Juste valeur
$78.48
Valeur potentielle
$92.70
Au
2026-09-18
Pourquoi le scénario peut fonctionner
Accelerating global adoption of premium silicone hydrogel daily disposable lenses (MyDay, clariti) across Europe and Asia, expanding revenue per wearer and driving consolidated operating margin expansion above 18.0%.
Ce qui changerait notre avis
European annual revenue growth decelerates below 1.0% YoY alongside sustained euro weakness.
We rate The Cooper Companies a Strong Buy based on durable cash flow compounding in specialty vision care and an attractive 41.94% upside to our Fair value of $78.48.
The house rating is Strong Buy. For an ordinary investor, this means the stock presents exceptional risk-adjusted return potential where predictable operating compounding is available at a favorable entry valuation.2
The report was prepared at a price of $55.29 on September 18, 2026. Against this level, our Fair value stands at $78.48, representing 41.94% upside, while our Potential value reaches $92.70 if expansion accelerates.
The primary risk that would alter this view is deceleration of European revenue growth below 1.0% YoY or consolidated operating margins falling below 14.0%. If optical retail destocking or currency depreciation contracts European volume, cash generation would weaken, slowing debt reduction on $2,783.6M of total debt.2,4,5
The core reason the investment can succeed is CooperVision's high wearer retention and ongoing patient upgrade into premium daily disposable silicone hydrogel contact lenses. This dynamic drives recurring revenue growth of 3.5% to 4.5% and sustained segment operating profit ($729.6M in FY2025), lifting free cash flow and expanding intrinsic value per share toward Fair value.3,5
Resilient Vision Care Compounding
CooperVision generates $2,743.8M in revenue and $729.6M in operating profit, driven by high wearer retention and an ongoing mix shift to silicone hydrogel daily disposables.5
Trading at 11.34x forward earnings, shares offer 41.94% upside to the house Fair value of $78.48, presenting an asymmetric risk-reward profile relative to medtech peers.2
Operating cash flow of $796.1M converts net income at 2.12x, fully covering $362.4M in capex and supporting steady deleveraging of total debt.2,4
Recommandation maison
We rate The Cooper Companies a Strong Buy because its dominant daily disposable contact lens franchise generates resilient operating cash flow that is priced at a substantial discount to intrinsic value.5
Présentation de l’entreprise
CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical offers a broad array of products and services focused on fertility and women's health. Its portfolio encompasses more than 600 products and services.
The Cooper Companies, Inc. (Cooper, the company ors the Company) is a global medical device company publicly traded on the Nasdaq (Nasdaq: COO). Cooper operates through two business units, CooperVision and CooperSurgical. The following table presents a summary of its business segment net sales:
§2 Cas baissierEN
Under a combined macro and operational downturn, euro depreciation and European optical retail softening reduce top-line compounding while Cooper Surgical operating margin remains depressed at 3.22%. With debt service on $2,783.6M of total debt absorbing cash at a 5.59% pre-tax cost of debt, consolidated operating margins compress toward 14.0%, testing historical trough valuation multiples.
The Bear scenario reflects prolonged macroeconomic weakness across European optical retail, adverse foreign currency translation, and aggressive private-label contact lens competition. Downside would be confirmed by gross margin contraction and persistent surgical segment stagnation, impairing earnings growth and compressing valuation multiples.
Comment cette thèse peut échouer
European contact lens volume contraction and severe euro depreciation
Deceleration of European revenue growth below 1.0% YoY weakens the international geographic penetration pillar and lowers fair value by -6.6%.
FV impact
-6.6%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Consolidated operating margin compression driven by surgical segment stagnation and corporate cost expansion
Signaux d'alerte précoce à surveiller
Les cinq évolutions qui affaibliraient notre thèse d’investissement.
Volume contraction across European optical retail chains coupled with currency depreciation that impairs international expansion.
Actuel :30.6% of FY2025 consolidated revenue ($1,253.2M)
Alerte siBelow 1.0% YoY growth
02
§3 Avantage concurrentielEN
Narrow
Cooper maintains a narrow economic moat grounded in high switching costs and proprietary designs across Cooper Vision daily disposable contact lenses. Prescribing optometrists exhibit significant behavioral inertia, as refitting patients requires uncompensated chair time and trial lenses. Silicone hydrogel formulations in MyDay and clariti create tangible clinical barriers that protect segment profitability ($729.6M operating profit in FY2025). However, reported ROIC of 4.22% remains below the 7.67% WACC, weighed down by historical acquisition goodwill of $3,853.4M, preventing a wide moat classification.
Profit économique
While Cooper Vision generates strong cash earnings ($729.6M segment operating profit), consolidated invested capital remains weighed down by $3,853.4M in goodwill, keeping reported ROIC below WACC of 7.67%.1,5
6.5/ 10
Narrow
Sources of advantage
01switching_costs — Optometrist prescribing habits and wearer reluctance to switch contact lens modalities support high customer retention and recurring demand across Cooper Vision's $2,743.8M revenue base.Moderate
02intangible_assets — Proprietary silicone hydrogel patents and specialized manufacturing techniques for toric and multifocal lenses sustain gross profit of $2,682.1M on $4,092.4M revenue (65.54% gross margin).
Menaces connues pour l'avantage
Menace
Gravité
Calendrier
Atténuation
Retail optical private-label competition and direct-to-consumer alternatives
medium
24-36 months
Continuous innovation in premium toric and multifocal silicone hydrogel daily modalities that optical chains cannot replicate with generic lines.
Foreign exchange volatility in key European distribution regions
The highlighted cell is Fair value when every assumption sits at its base level ($78.48). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $500.4M after modeled reinvestment of $0, with terminal value at 39.3% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Core vision care revenue expands at a moderate pace aligned with demographic correction needs
Consolidated operating margins remain defensive within historical ranges
Surplus cash flow is directed toward continuous debt paydown
The Base case envisions steady compounding driven by ongoing conversion to premium daily disposable contact lenses, defensive gross margins, and gradual deleveraging. Performance tracks toward Fair value of $78.48, supported by stable replacement demand across optometry networks. The thesis would be challenged if European revenue decelerates or if surgical segment margins fail to recover.
Maintain Strong Buy; Maintain position weighting and confirm international optical retail volume momentum at the subsequent quarterly checkpoint.
Déclencheur: Consolidated revenue and diluted earnings exceeding consensus upper bounds driven by accelerated daily disposable adoption
Outperformance confirms market share gains in premium silicone hydrogel lenses and validates operating leverage toward Fair value of $78.48.
Conforme
Maintain Strong Buy; Hold existing allocation, verify surgical segment margin stabilization, and monitor working capital discipline.
Déclencheur: Quarterly revenue and earnings matching consensus targets with stable gross margins
In-line execution reaffirms steady compounding thesis and supports ongoing convergence toward Fair value of $78.48.
Manqué
Downgrade to Buy; Re-evaluate surgical segment cost integration and reassess position sizing if margin contraction persists across consecutive reporting periods.
Management balanced capital deployment in FY2025 between $362.4M in manufacturing capex, $290.1M in share buybacks, and net debt reduction of $79.9M, steadily deleveraging total debt of $2,783.6M.
Reported GAAP return on invested capital of 4.22% is suppressed by $3,853.4M in goodwill from past acquisitions, masking underlying operating cash generation.
Reported ROIC of 4.22% trails WACC of 7.67%, though core vision operations generate $729.6M in operating profit on tangible assets.
Vision care franchise generates superior operating profitability relative to surgical instruments
Cooper Vision achieved 26.59% operating margin ($729.6M operating profit on $2,743.8M revenue) compared to Cooper Surgical's 3.22% operating margin ($43.4M on $1,348.6M revenue).
Consolidated margin expansion depends heavily on surgical segment turnaround and sustained daily disposable mix shifts in vision care.
Operating cash generation comfortably covers annual debt service
Operating cash flow of $796.1M supports $100.0M of annual and debt service on total debt of $2,783.6M.
Dernier chiffre d’affaires4,1 Md $USTCAC du chiffre d’affaires +8,5 %
Marge opérationnelle16,7 %10 périodes fiscales
Dernier flux de trésorerie disponible433,7 M $USFY2025
Dette nette2,7 Md $USFY2025
Décomposition du compte de résultatComment la taille de l’activité se traduit en bénéfice publié.
StockMarketAgent.AI
Chiffre d'affaires4,1 Md $USCoût des ventes−1,4 Md $USMarge brute2,7 Md $USCharges d’exploitation−2 Md $USRésultat d'exploitation682,9 M $USÉléments hors exploitation et impôts−308 M $USRésultat net374,9 M $US
Données de l’historique financier
Chiffre d'affaires
4 092 400 000 $US
Coût des ventes
1 410 300 000 $US
Marge brute
2 682 100 000 $US
Charges d’exploitation
1 999 200 000 $US
Résultat d'exploitation
682 900 000 $US
Éléments hors exploitation et impôts
-308 000 000 $US
Résultat net
374 900 000 $US
Aperçu du bilanComment les actifs publiés sont détenus et financés pour la période sélectionnée.
StockMarketAgent.AI
Composition des actifsFinancé par
Total de l’actif12,4 Md $USTrésorerie110,6 M $USActifs courants2,1 Md $USTotal du passif4,2 Md $USPassifs courants1,1 Md $USCapitaux propres8,2 Md $US
Données de ventilation du bilan
Total de l’actif
12 394 800 000 $US
Trésorerie
110 600 000 $US
Actifs courants
2 106 400 000 $US
Total du passif
4 155 700 000 $US
Passifs courants
1 112 800 000 $US
Capitaux propres
8 239 100 000 $US
Passerelle des flux de trésorerieComment le flux de trésorerie d’exploitation est devenu du flux de trésorerie disponible en FY2025.
StockMarketAgent.AI
Rapprochement des flux d’exploitation
Résultat net374,9 M $USDotations aux amortissements+377,4 M $USRémunération en actions+70,5 M $USAutres ajustements opérationnels−26,7 M $USFlux de trésorerie d'exploitation796,1 M $US
Rapprochement de la trésorerie d’ouverture à la clôture
Trésorerie d’ouverture107,7 M $USFlux de trésorerie d'exploitation+796,1 M $USFlux d’investissement−372,9 M $USFlux de financement−425,9 M $USEffet de change+5,6 M $USTrésorerie de clôture110,6 M $US
796,1 M $US − 362,4 M $USFlux de trésorerie disponible 433,7 M $US
Données de la passerelle des flux de trésorerie
Résultat net
374 900 000 $US
Entrées d’exploitation
822 800 000 $US
Dotations aux amortissements
377 400 000 $US
Rémunération en actions
70 500 000 $US
Flux de trésorerie d'exploitation
796 100 000 $US
Sorties d’exploitation
26 700 000 $US
Trésorerie disponible
909 400 000 $US
Trésorerie d’ouverture
107 700 000 $US
Effet de change
5 600 000 $US
Sorties d’investissement
372 900 000 $US
Capex
362 400 000 $US
Autres activités d’investissement
10 500 000 $US
Sorties de financement
425 900 000 $US
Rachats d’actions
290 100 000 $US
Remboursement net de dette
79 900 000 $US
Autres activités de financement
55 900 000 $US
Trésorerie de clôture
110 600 000 $US
Flux d’investissement
-372 900 000 $US
Flux de financement
-425 900 000 $US
Chiffre d’affaires par secteur opérationnelPart du chiffre d’affaires total pour 2025-10-31.
4,1 Md $USChiffre d’affaires total
Chiffre d’affaires par secteur opérationnelPart
Cooper Vision2,7 Md $US67 %+5,2 % sur un an
Cooper Surgical1,3 Md $US33 %+4,9 % sur un an
Source: SEC EDGAR · Déposé le 2025-12-05 · SEC EDGAR
Données de répartition du chiffre d’affaires: Chiffre d’affaires par secteur opérationnel
Chiffre d’affaires par secteur opérationnel
Chiffre d'affaires
Part
sur un an
Cooper Vision
2,7 Md $US
67 %
5,2 %
Cooper Surgical
1,3 Md $US
33 %
4,9 %
Chiffre d’affaires par zone géographiquePart du chiffre d’affaires total pour 2025-10-31.
4,1 Md $USChiffre d’affaires total
Chiffre d’affaires par zone géographiquePart
United States2,1 Md $US50,2 %+4,5 % sur un an
Europe1,3 Md $US30,6 %+8,4 % sur un an
Rest Of The World785,2 M $US19,2 %+1,5 % sur un an
Source: SEC EDGAR · Déposé le 2025-12-05 · SEC EDGAR
Données de répartition du chiffre d’affaires: Chiffre d’affaires par zone géographique
Chiffre d’affaires par zone géographique
Chiffre d'affaires
Part
sur un an
United States
2,1 Md $US
50,2 %
4,5 %
Europe
1,3 Md $US
30,6 %
8,4 %
Rest Of The World
785,2 M $US
19,2 %
1,5 %
Chiffre d’affaires et résultatsComment la taille de l’activité se traduit en bénéfice publié.
Trésorerie et detteLiquidités disponibles face à l’endettement total.
Génération de trésorerieFlux de trésorerie d’exploitation comparé au flux de trésorerie disponible.
RentabilitéÉvolution des marges brute, opérationnelle et nette.
Données financières ponctuelles utilisées dans l’analyse du 2026-09-20.
The Cooper Companies Inc. (COO) trades at 11.3x forward earnings against a peer median of 12.0x. Its EV/EBITDA of 14.1x compares with a peer median of 13.9x. The comparison uses 4 peers: Align Technology Inc., Solventum Corporation, Intuitive Surgical Inc. and Baxter International Inc., as of 2026-09-19 to 2026-09-20.
§10 Secteur et cycleEN
Phase du cycle
Expansion
Annual capital expenditure of $362.4M represents 8.86% of revenue, supporting automated daily disposable contact lens manufacturing lines in line with industry capex-to-depreciation benchmarks of 0.80x.4
Cycle haussier
Accelerating global conversion from reusable lenses to premium single-use daily disposables, paired with rising worldwide myopia prevalence and demographic expansion in presbyopia treatments.
Cycle baissier
Optical retail destocking, consumer trade-down toward private label lenses during macroeconomic slowdowns, and adverse foreign exchange translation across European markets.
Tendances séculaires
Tendance
Impact
Note
Global shift toward daily disposable silicone hydrogel contact lenses
positive
Wearers steadily upgrade to single-use modalities for ocular health and convenience, expanding annual revenue per patient.
Rising global myopia diagnosis and pediatric myopia management
positive
Increased screen time drives worldwide myopia rates, sustaining long-term international volume expansion across Europe and Asia.
Consolidation of optical retail chains and private-label proliferation
negative
Large retail optical groups exert bargaining power on lens manufacturers, pressuring wholesale margins on standard spherical designs.
Positionnement
Cooper occupies a well-insulated position as a leading global supplier of specialty toric and multifocal lenses, shielding it from standard spherical commodity pricing.
§11 Gestion de positionEN
Taille de position
4-6%
Non-discretionary vision care demand, robust operating cash flow, and substantial valuation discount support an above-benchmark weighting.
Risque
Risk is mitigated by non-discretionary wearer replacement habits, recurring revenue in daily disposables, and ongoing debt paydown from annual operating cash flow of $796.1M.
CooperVision's high customer retention and daily disposable mix shift support durable 3.5% to 4.5% top-line growth and resilient operating cash generation.5
Valuation Opportunist
Buy
Trading at 11.34x forward earnings, shares sit well below the house Fair value of $78.48, providing a 41.94% upside margin of safety.2
Risk-Conscious / Defensive
Buy
Non-discretionary vision care demand and $796.1M in operating cash flow comfortably support debt service on $2,783.6M of total debt.2,4
§14 Recommandation finaleEN
Action
Achat fort
We recommend a Strong Buy on The Cooper Companies based on durable cash compounding from CooperVision's daily disposable contact lens franchise, trading at a 29.55% discount to our Fair value of $78.48.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Working capital deterioration or contact lens inventory build reducing cash available for debt service on $2,783.6M total debt.
Actuel :$796.1M in FY2025
Alerte siBelow $600.0M
Moderate
03cost_advantage — High-volume automated daily disposable manufacturing facilities in the United Kingdom and Costa Rica yield efficient per-unit production economics across global distribution channels.Narrow
medium
12-18 months
Natural currency hedging via European operational infrastructure and diversified rest-of-world revenue streams of $785.2M.5
The Bull case models accelerated market share gains in specialty silicone hydrogel daily lenses across Europe and Asia, accompanied by operational integration in Cooper Surgical that lifts segment margins. This outcome delivers Potential value of $92.70 as valuation multiples expand. Slower adoption of daily modalities would disconfirm this trajectory.
Pourquoi c'est important
Europe generates substantial consolidated sales; sustained growth confirms geographic penetration while weakness signals macro drag.
03
Métrique:
Cooper Surgical operating profitability
ActuelConstrained by integration expenses and operational restructuring
Pourquoi c'est important
Surgical margin expansion is required to alleviate the profitability drag on consolidated operating results.
